Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD

In part 2 of this interview, Michael Mina, MD, PhD, discusses LIBERTY study data showing that VYD2311 boosted neutralizing activity without interfering with mRNA COVID-19 vaccine response.

A lipidologist outlines how PREVENT, coronary calcium scoring, and restored LDL-C targets guide personalized lipid therapy and where pharmacists fit in.

Pharmacists play a large role in mavacamten care, screening for interacting drugs that can raise exposure and may require dose adjustment or withholding.

Validating patient concerns and then reframing them around stroke prevention can help pharmacists counsel patients who worry that statins harm memory.

Michael Mina, MD, PhD, discusses phase 3 LIBERTY study data showing that the monoclonal antibody VYD2311, alone or combined with an mRNA COVID-19 vaccine, was associated with fewer adverse events than vaccination alone.

Alexander Turchin, MD, MS, recommends shared decision-making, time-limited lifestyle trials, and gentle persistence to move patients toward statins.

A lipidologist traces patient fears to 2012 FDA label language and reviews observational and randomized data showing no cognitive harm from statins.

Pharmacists can prompt once-in-a-lifetime Lp(a) testing, reinforce statin adherence, and put muscle aches in context, according to the NLA president.